Constipation, a prevalent and often underestimated condition, poses significant challenges in clinical practice. It is essential to adopt a comprehensive approach to effectively manage this condition, considering its multifactorial nature and the potential for significant impact on the patient's quality of life.
Constipation is not merely a symptom but a complex disorder with multifaceted etiology. It can be primary, due to colonic or anorectal dysfunction, or secondary to systemic diseases, medications, or lifestyle factors. A thorough understanding of these underlying causes is crucial to devise an effective management plan.
Diagnosis involves a careful patient history, physical examination, and necessary investigations. The Rome IV criteria provide a standardized definition for functional constipation, but clinicians must be vigilant for alarm signs, such as weight loss, rectal bleeding, or family history of colorectal cancer, which may necessitate further investigations like colonoscopy.
Treatment should be individualized, starting with lifestyle modifications and dietary changes, including increased fiber intake and hydration. Over-the-counter laxatives are often the first line of pharmacological intervention. However, for patients with refractory constipation, newer agents like secretagogues can be beneficial. Biofeedback therapy has shown efficacy in patients with dyssynergic defecation. In refractory cases, surgical options may be considered.
Patient education is an integral part of the management plan. Patients should be informed about the nature of the condition, the importance of adherence to treatment, potential side effects of medications, and the need for regular follow-up.
Managing constipation in clinical practice requires a comprehensive approach that considers the multifactorial nature of the condition. A thorough understanding of the underlying causes, an individualized treatment plan, and patient education are key to effectively manage this common but often underestimated condition.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation